Sarah J. Billups
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah J. Billups has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Rachel M. F. Heilmann
Kaiser Permanente Colorado and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora
2 shared publicationsThomas Delate
Kaiser Permanente, Aurora, CO; Clinical Instructor, College of Pharmacy, University of Colorado Denver
2 shared publications- Thomas Delate
Kaiser Permanente National Pharmacy
2 shared publications Adriane N. Irwin
Oregon State University College of Pharmacy, Corvallis, Oregon; Pharmacy Department, Kaiser Permanente Colorado, Aurora, Colorado
1 shared publicationAlexander P Block
1 shared publicationBarbara Hoover
College of Pharmacy, University of Colorado, Denver
1 shared publication
Latest Publications
- 1 March 2017
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 23 (3) , 346-354
Opioid Use for Pain Management After Implementation of a Medicaid Short-Acting Opioid Quantity Limit
BACKGROUND: The United States is currently experiencing an opioid abuse epidemic. Many policies and programs have been implemented at local, state, and national levels in an attempt to decrease prescription opioid addiction and overdose. On August 1, 2014, Colorado Medicaid implemented a policy change that limited the quantity of short-acting opioids (SAOs) that could be filled through the Medicaid benefit to no more than 4 tablets per day, or 120 tablets in 30 days. OBJECTIVE: To compare mean total daily dose (TDD) of opioids purchased by Kaiser Permanente Colorado (KPCO) Medicaid patients before and after implementation of the Medicaid SAO quantity limit. METHODS: This investigation used a pre/post study design to compare opioid use in Medicaid-eligible patients during the 90 days before implementation of the Medicaid quantity limit on August 1, 2014, and 90 days after full implementation of the change on December 31, 2014. The study was conducted at KPCO, an integrated care delivery system providing medical care for approximately 615,000 patients, of which over 54,000 are Medicaid members. Electronic medical and pharmacy records were used to identify patients and assess medication use. RESULTS: There was a small difference in opioid use in the population of Medicaid opioid users as evidenced by the median TDD of oral morphine equivalents (OME) purchased decreasing from 6.8 mg (IQR = 2.2-25.8) in the pre-implementation period to 6.6 mg (IQR = 1.7-24.0) in the postimplementation period (P = 0.027). The proportion of patients purchasing more than 120 mg OME per day and the proportion of patients purchasing long-acting opioids (LAOs) did not change significantly from the pre- to postimplementation period (OME > 120 of 4.2% vs. 3.6%, respectively, P = 0.290; LAO use of 12.9% vs. 13.6%, respectively, P = 0.465). CONCLUSIONS: This study found a statistically significant 3% decrease of 0.2 mg OME per day in the primary study population. A 24% reduction of 10 mg OME per day before and after implementation of the Medicaid SAO quantity limit was found in those patients identified as exceeding the Medicaid SAO quantity limit at baseline. These patients tended to be purchasing low to moderate total daily doses of opioids at baseline. DISCLOSURES: Internal funding was provided by the Department of Pharmacy at Kaiser Permanente Colorado. There are no external funding sources to disclose. Riggs, Milchak, Patel, and Heilmann are employed by Kaiser Permanente Colorado. The authors report no other potential conflicts of interest. Study concept and design were contributed by Riggs, Heilmann, and Billups, along with the other authors. Billups collected the data, and data interpretation was performed by Riggs, Milchak, and Flores, with assistance from the other authors. The manuscript was written primarily by Riggs, along with Flores, and revised by Billups, Milchak, Patel, and Heilmann.
- 1 March 2017
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 23 (3) , 346-354
Opioid Use for Pain Management After Implementation of a Medicaid Short-Acting Opioid Quantity Limit
BACKGROUND: The United States is currently experiencing an opioid abuse epidemic. Many policies and programs have been implemented at local, state, and national levels in an attempt to decrease prescription opioid addiction and overdose. On August 1, 2014, Colorado Medicaid implemented a policy change that limited the quantity of short-acting opioids (SAOs) that could be filled through the Medicaid benefit to no more than 4 tablets per day, or 120 tablets in 30 days. OBJECTIVE: To compare mean total daily dose (TDD) of opioids purchased by Kaiser Permanente Colorado (KPCO) Medicaid patients before and after implementation of the Medicaid SAO quantity limit. METHODS: This investigation used a pre/post study design to compare opioid use in Medicaid-eligible patients during the 90 days before implementation of the Medicaid quantity limit on August 1, 2014, and 90 days after full implementation of the change on December 31, 2014. The study was conducted at KPCO, an integrated care delivery system providing medical care for approximately 615,000 patients, of which over 54,000 are Medicaid members. Electronic medical and pharmacy records were used to identify patients and assess medication use. RESULTS: There was a small difference in opioid use in the population of Medicaid opioid users as evidenced by the median TDD of oral morphine equivalents (OME) purchased decreasing from 6.8 mg (IQR = 2.2-25.8) in the pre-implementation period to 6.6 mg (IQR = 1.7-24.0) in the postimplementation period (P = 0.027). The proportion of patients purchasing more than 120 mg OME per day and the proportion of patients purchasing long-acting opioids (LAOs) did not change significantly from the pre- to postimplementation period (OME > 120 of 4.2% vs. 3.6%, respectively, P = 0.290; LAO use of 12.9% vs. 13.6%, respectively, P = 0.465). CONCLUSIONS: This study found a statistically significant 3% decrease of 0.2 mg OME per day in the primary study population. A 24% reduction of 10 mg OME per day before and after implementation of the Medicaid SAO quantity limit was found in those patients identified as exceeding the Medicaid SAO quantity limit at baseline. These patients tended to be purchasing low to moderate total daily doses of opioids at baseline. DISCLOSURES: Internal funding was provided by the Department of Pharmacy at Kaiser Permanente Colorado. There are no external funding sources to disclose. Riggs, Milchak, Patel, and Heilmann are employed by Kaiser Permanente Colorado. The authors report no other potential conflicts of interest. Study concept and design were contributed by Riggs, Heilmann, and Billups, along with the other authors. Billups collected the data, and data interpretation was performed by Riggs, Milchak, and Flores, with assistance from the other authors. The manuscript was written primarily by Riggs, along with Flores, and revised by Billups, Milchak, Patel, and Heilmann.
- 24 March 2015
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 35 (3) , 243-250
Labor Costs and Economic Impact of a Primary Care Clinical Pharmacy Service on Postfracture Care in Postmenopausal Women
Study Objective: To compare costs associated with two osteoporosis management interventions and to quantify cost avoidance due to projected hip fracture prevention.Design: Labor and cost analysis within a retrospective cohort study.Setting: Integrated health care delivery system.Patients or Participants: Women aged 67 or older with a documented fracture between January 1 and December 31, 2007, managed by either a Clinical Pharmacy Osteoporosis Management Service (CPOMS) or comparator service using a registered nurse (RN). Recommendations included dual‐energy x‐ray absorptiometry (DEXA) scans and/or bisphosphonate therapy as appropriate.Measurement and Main Results: The primary end points were cost per patient reviewed, cost per patient achieving the quality end point of completing a DEXA scan or purchasing an antiosteoporosis medication, and cost avoidance due to projected hip fracture prevention. A total of 1129 women were managed by either CPOMS (n=827) or the comparator service (n=302). The cost of provider time for CPOMS and comparator group interventions was $25 ($21–$30) and $34 ($21–$53) per patient reviewed, respectively. The cost per patient achieving the quality end point was $92 ($77–$112) and $198 ($124–$307), respectively. If women in the CPOMS group persisted in receiving their bisphosphonate for 1 year, approximately two additional hip fractures would be avoided per 1000 patients reviewed. Based on this model, the projected annual cost of osteoporosis care for 1000 women was $619,736 (CPOMS) versus $726,887 (comparator service).Conclusions: The CPOMS resulted in comparable cost per patient reviewed but a lower cost per patient achieving quality end points. When including costs associated with projected hip fractures, CPOMS was less expensive than the comparator group because more patients initiated drug therapy, which resulted in fewer projected hip fractures. From the health care payer's perspective, the CPOMS intervention is associated with a lower cost per patient achieving treatment recommendations while providing future cost savings because of fewer hip fractures.
- 24 March 2015
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 35 (3) , 243-250
Labor Costs and Economic Impact of a Primary Care Clinical Pharmacy Service on Postfracture Care in Postmenopausal Women
Study Objective: To compare costs associated with two osteoporosis management interventions and to quantify cost avoidance due to projected hip fracture prevention.Design: Labor and cost analysis within a retrospective cohort study.Setting: Integrated health care delivery system.Patients or Participants: Women aged 67 or older with a documented fracture between January 1 and December 31, 2007, managed by either a Clinical Pharmacy Osteoporosis Management Service (CPOMS) or comparator service using a registered nurse (RN). Recommendations included dual‐energy x‐ray absorptiometry (DEXA) scans and/or bisphosphonate therapy as appropriate.Measurement and Main Results: The primary end points were cost per patient reviewed, cost per patient achieving the quality end point of completing a DEXA scan or purchasing an antiosteoporosis medication, and cost avoidance due to projected hip fracture prevention. A total of 1129 women were managed by either CPOMS (n=827) or the comparator service (n=302). The cost of provider time for CPOMS and comparator group interventions was $25 ($21–$30) and $34 ($21–$53) per patient reviewed, respectively. The cost per patient achieving the quality end point was $92 ($77–$112) and $198 ($124–$307), respectively. If women in the CPOMS group persisted in receiving their bisphosphonate for 1 year, approximately two additional hip fractures would be avoided per 1000 patients reviewed. Based on this model, the projected annual cost of osteoporosis care for 1000 women was $619,736 (CPOMS) versus $726,887 (comparator service).Conclusions: The CPOMS resulted in comparable cost per patient reviewed but a lower cost per patient achieving quality end points. When including costs associated with projected hip fractures, CPOMS was less expensive than the comparator group because more patients initiated drug therapy, which resulted in fewer projected hip fractures. From the health care payer's perspective, the CPOMS intervention is associated with a lower cost per patient achieving treatment recommendations while providing future cost savings because of fewer hip fractures.
- 1 September 2014
- Vol. 20 (9) , e380-7
Cost-effectiveness evaluation of a home blood pressure monitoring program.
To evaluate the health system cost of a home blood pressure monitoring (HBPM) program versus usual care in an integrated healthcare system. This cost-effectiveness analysis was based upon a previously completed randomized controlled trial of 348 hypertensive patients, in which mean systolic blood pressure (BP) was lowered 21 versus 8 mm Hg in the HBPM and usual care groups, respectively, and BP control was achieved in 54% versus 35% of patients (P < .001). This analysis compared direct costs from the health plan perspective, including clinic visits, e-mail and telephone encounters, laboratory tests, medications, hospitalizations, and emergency department visits between the 2 groups. Primary outcomes were the incremental hypertension care-related cost of HBPM per mm Hg lowering of systolic BP per patient, per additional BP controlled, and per life-year gained. Median hypertension-related cost per patient over 6 months was $455 in the HBPM group and $179 for usual care (P < .001). This increase was attributable to additional e-mail and telephone encounters, greater antihypertensive medication use, additional laboratory monitoring, and the BP monitor. Median total cost per patient was $1530 and $1283 for the HBPM and usual care groups, respectively (P = .034). The HBPM program increased hypertension-related expenditures by $20.50 per mm Hg lowering of systolic BP, $1331 per additional patient achieving BP control at 6 months, and $3330 per life-year gained. The HBPM program requires investment in outpatient encounters, medications, and laboratory monitoring, but produces significantly improved BP control.
- 1 September 2014
- Vol. 20 (9) , e380-7
Cost-effectiveness evaluation of a home blood pressure monitoring program.
To evaluate the health system cost of a home blood pressure monitoring (HBPM) program versus usual care in an integrated healthcare system. This cost-effectiveness analysis was based upon a previously completed randomized controlled trial of 348 hypertensive patients, in which mean systolic blood pressure (BP) was lowered 21 versus 8 mm Hg in the HBPM and usual care groups, respectively, and BP control was achieved in 54% versus 35% of patients (P < .001). This analysis compared direct costs from the health plan perspective, including clinic visits, e-mail and telephone encounters, laboratory tests, medications, hospitalizations, and emergency department visits between the 2 groups. Primary outcomes were the incremental hypertension care-related cost of HBPM per mm Hg lowering of systolic BP per patient, per additional BP controlled, and per life-year gained. Median hypertension-related cost per patient over 6 months was $455 in the HBPM group and $179 for usual care (P < .001). This increase was attributable to additional e-mail and telephone encounters, greater antihypertensive medication use, additional laboratory monitoring, and the BP monitor. Median total cost per patient was $1530 and $1283 for the HBPM and usual care groups, respectively (P = .034). The HBPM program increased hypertension-related expenditures by $20.50 per mm Hg lowering of systolic BP, $1331 per additional patient achieving BP control at 6 months, and $3330 per life-year gained. The HBPM program requires investment in outpatient encounters, medications, and laboratory monitoring, but produces significantly improved BP control.
- 1 January 2014
- Vol. 20 (12) , 995-1001
Out-of-plan pharmacy use: insights into patient behavior.
The purpose of this study was to identify and describe patient rationales for filling prescriptions at an out-of-plan pharmacy (OOPP). A cross-sectional survey conducted in February 2013 among a random sample of 1000 patients. Adult Kaiser Permanente Colorado (KPCO) patients who had a prescription electronically issued to an OOPP in November 2012 were surveyed. The study questionnaire was developed using items obtained from the literature and prepared de novo, as needed. The questionnaire included items regarding whether the electronic prescription issued to an OOPP was filled; if filled, which OOPP was used; factors that may have influenced the use of an OOPP; and the patient's ability to afford medications. Responses to the survey were tabulated and reported as percentages. The survey response rate was 38%. Respondents (N=382) had a mean age of 61 years, 35% were males, and anti-hypertensives were their most common OOPP prescription. Overall, 330 (86%) respondents reported that they had their prescription filled at an OOPP. The most commonly reported OOPPs utilized were supermarket pharmacies (42%). Factors that influenced the decision to use an OOPP included the prescription being less expensive (58%), the OOPP had a discount generic prescription program (57%), and the OOPP's location was convenient (44%). Thirty-nine percent of respondents reported that using an OOPP helped them afford their prescriptions. Prescription cost and pharmacy convenience were identified as the most significant drivers of OOPP use. Future research should be conducted to assess the health-related consequences of OOPP use.
- 1 January 2014
- Vol. 20 (12) , 995-1001
Out-of-plan pharmacy use: insights into patient behavior.
The purpose of this study was to identify and describe patient rationales for filling prescriptions at an out-of-plan pharmacy (OOPP). A cross-sectional survey conducted in February 2013 among a random sample of 1000 patients. Adult Kaiser Permanente Colorado (KPCO) patients who had a prescription electronically issued to an OOPP in November 2012 were surveyed. The study questionnaire was developed using items obtained from the literature and prepared de novo, as needed. The questionnaire included items regarding whether the electronic prescription issued to an OOPP was filled; if filled, which OOPP was used; factors that may have influenced the use of an OOPP; and the patient's ability to afford medications. Responses to the survey were tabulated and reported as percentages. The survey response rate was 38%. Respondents (N=382) had a mean age of 61 years, 35% were males, and anti-hypertensives were their most common OOPP prescription. Overall, 330 (86%) respondents reported that they had their prescription filled at an OOPP. The most commonly reported OOPPs utilized were supermarket pharmacies (42%). Factors that influenced the decision to use an OOPP included the prescription being less expensive (58%), the OOPP had a discount generic prescription program (57%), and the OOPP's location was convenient (44%). Thirty-nine percent of respondents reported that using an OOPP helped them afford their prescriptions. Prescription cost and pharmacy convenience were identified as the most significant drivers of OOPP use. Future research should be conducted to assess the health-related consequences of OOPP use.
- 20 April 2011
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 45 (4) , 485-491
Injury in an Elderly Population Before and After Initiating a Skeletal Muscle Relaxant
BACKGROUND: Quality guidelines recommend avoidance of skeletal muscle relaxants in patients 65 years and older, but this recommendation is based on expert opinion, not evidence. OBJECTIVE: To describe an elderly population using skeletal muscle relaxants and compare the incidence of physical injury among these patients before and after initiation of the medication. METHODS: This was a retrospective, pre-post cohort analysis, with each patient serving as his/her own control. In a population of elderly patients who purchased a prescription for a skeletal muscle relaxant, the primary outcome was to compare the proportion of patients experiencing an injury in a 60-day period prior to initiating the drug to the proportion experiencing an injury in the 60 days immediately following the purchase date. RESULTS: Of the 11,875 patients included in the study, 108 (0.9%) experienced an injury during the baseline period and 144 (1.2%) experienced an injury in the 60-day follow-up period (unadjusted OR 1.35; 95% CI 1.05 to 1.75; adjusted OR 1.35; 95% CI 1.01 to 1.81). A total of 333 patients needed to be treated with a skeletal muscle relaxant to result in 1 additional injury. Independent predictors of an injury included a history of an injury in the previous 6 months (OR 3.01; 95% CI 1.54 to 5.88) and older age (OR 1.06; 95% CI 1.04 to 1.09). CONCLUSIONS: The absolute increase in risk of injury in this population using a skeletal muscle relaxant was small but statistically significant. Cautionary use of these medications in the elderly continues to be advisable, but their use in selected patients 65 years and older could be considered if the expected benefits outweigh the small increased risk of injury. More study is needed to quantify the benefits versus risks of these medications in this population.
- 20 April 2011
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 45 (4) , 485-491
Injury in an Elderly Population Before and After Initiating a Skeletal Muscle Relaxant
BACKGROUND: Quality guidelines recommend avoidance of skeletal muscle relaxants in patients 65 years and older, but this recommendation is based on expert opinion, not evidence. OBJECTIVE: To describe an elderly population using skeletal muscle relaxants and compare the incidence of physical injury among these patients before and after initiation of the medication. METHODS: This was a retrospective, pre-post cohort analysis, with each patient serving as his/her own control. In a population of elderly patients who purchased a prescription for a skeletal muscle relaxant, the primary outcome was to compare the proportion of patients experiencing an injury in a 60-day period prior to initiating the drug to the proportion experiencing an injury in the 60 days immediately following the purchase date. RESULTS: Of the 11,875 patients included in the study, 108 (0.9%) experienced an injury during the baseline period and 144 (1.2%) experienced an injury in the 60-day follow-up period (unadjusted OR 1.35; 95% CI 1.05 to 1.75; adjusted OR 1.35; 95% CI 1.01 to 1.81). A total of 333 patients needed to be treated with a skeletal muscle relaxant to result in 1 additional injury. Independent predictors of an injury included a history of an injury in the previous 6 months (OR 3.01; 95% CI 1.54 to 5.88) and older age (OR 1.06; 95% CI 1.04 to 1.09). CONCLUSIONS: The absolute increase in risk of injury in this population using a skeletal muscle relaxant was small but statistically significant. Cautionary use of these medications in the elderly continues to be advisable, but their use in selected patients 65 years and older could be considered if the expected benefits outweigh the small increased risk of injury. More study is needed to quantify the benefits versus risks of these medications in this population.
- 15 January 2009
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 18 (3) , 253-257
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations
- 15 January 2009
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 18 (3) , 253-257
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations
- Open Access
- 1 April 2006
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care Pharmacy
- Vol. 12 (3) , 246-253
Assessment of Clinical, Service, and Cost Outcomes of a Conversion Program of Sumatriptan to Rizatriptan ODT in Primary Care Patients With Migraine Headaches
OBJECTIVE: Managed care organizations can increase the value of drug therapy by negotiating discounts on drug acquisition costs with pharmaceutical manufacturers and promoting use of preferred drugs, including the conversion of patients to preferred medications. This investigation was designed to assess conversion success, migraine drug utilizations, and patient satisfaction with a clinical pharmacist-managed conversion program from sumatriptan to rizatriptan ODT, both formulary drugs. METHODS: This was a retrospective cohort study conducted in a managed care organization for patients aged 18 years or older who had picked up at least one outpatient prescription for any sumatriptan dosage form at the pharmacy between January 2002 and June 2002. Patients pharmacy and medical data were reviewed to assess eligibility (e.g., no history of rizatriptan failure) for conversion from sumatriptan to rizatriptan orally disintegrating tablet (ODT). There was no copayment difference for members for rizatriptan ODT versus sumatriptan. A questionnaire was developed to assess 2 domains: (1) patient satisfaction with the medication conversion process and (2) preference for rizatriptan ODT or sumatriptan. A random sample of 315 patients who initiated conversion to rizatriptan ODT was surveyed. Electronic pharmacy claims were reviewed to determine the number of patients who were successfully converted from sumatriptan to rizatriptan ODT. Pharmacy expenditures and total health care utilization and expenditures in the 180 days prior to (baseline) and after the conversion (followup) to rizatriptan ODT were compared for the cohorts of subjects who were successfully converted and those patients who were not successfully converted. RESULTS: Therapeutic conversion from sumatriptan to rizatriptan ODT was attempted in 457 patients; 214 (47%) were successfully converted. The only difference between the 2 cohorts at baseline for the 6 months prior to attempted conversion was a higher mean number of sumatriptan doses per patient per month (PPPM) in the 243 failed conversions (mean 3.5, SD 2.9) compared with the 214 successful conversions (mean 2.8, SD 2.8, P =0.003). The median triptan doses increased by 1.0 PPPM in both cohorts (P =0.882), from 2.0 to 3.0 doses PPPM in the group of successful conversions and from 2.7 to 4.0 in the group of unsuccessful conversions. The survey response rate was 55% for both successful and for unsuccessful conversions. More than 90% of the patients in both cohorts were satisfied with the level of care provided by the clinical pharmacy staff during medication conversion, and there was no difference between the 2 cohorts in patient satisfaction (P=0.761). Rizatriptan ODT was preferred by 68.0% and 8.5% of successful and failed conversion subjects, respectively (P less than0.001). Using representative group purchase prices, triptan expenditures for successful conversion subjects were reduced by a median of -$2 (6 %) PPPM while triptan expenditures for unsuccessful conversions increased by a median of $8 (P less than0.001). There were no differences for either cohort in median PPPM changes in migraine-related office visits (0.0 median change in office visits, P =0.748) or office-visit costs ($0 median change, P =0.861) for preconversion versus postconversion attempts Regression modeling identified that lower total counts of sumatriptan doses filled during baseline period was an independent predictor of successful conversion to rizatriptan ODT (P less than0.001). There was an average of 3.5 triptan medication fills per patient for successful conversion during the 6-month follow-up period, with 78% of these subjects filling at least 2 prescriptions for rizatriptan ODT during this period. CONCLUSIONS: This conversion program for sumatriptan to rizatriptan ODT was successful in converting almost half of primary care patients to the preferred product despite the absence of a copayment incentive for members to agree to the conversion. There were no measurable medical or economic consequences of the conversion, and patient satisfaction with the quality of care was maintained. Future efforts are likely to have a higher success rate if focused on converting patients with less-severe migraine headaches, as measured by the need for baseline rescue medication, since lower acuity was the only independent predictor of successful conversion in this conversion program for 2 triptan drugs.
- 1 April 2006
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care Pharmacy
- Vol. 12 (3) , 246-253
Open AccessAssessment of Clinical, Service, and Cost Outcomes of a Conversion Program of Sumatriptan to Rizatriptan ODT in Primary Care Patients With Migraine Headaches
OBJECTIVE: Managed care organizations can increase the value of drug therapy by negotiating discounts on drug acquisition costs with pharmaceutical manufacturers and promoting use of preferred drugs, including the conversion of patients to preferred medications. This investigation was designed to assess conversion success, migraine drug utilizations, and patient satisfaction with a clinical pharmacist-managed conversion program from sumatriptan to rizatriptan ODT, both formulary drugs. METHODS: This was a retrospective cohort study conducted in a managed care organization for patients aged 18 years or older who had picked up at least one outpatient prescription for any sumatriptan dosage form at the pharmacy between January 2002 and June 2002. Patients pharmacy and medical data were reviewed to assess eligibility (e.g., no history of rizatriptan failure) for conversion from sumatriptan to rizatriptan orally disintegrating tablet (ODT). There was no copayment difference for members for rizatriptan ODT versus sumatriptan. A questionnaire was developed to assess 2 domains: (1) patient satisfaction with the medication conversion process and (2) preference for rizatriptan ODT or sumatriptan. A random sample of 315 patients who initiated conversion to rizatriptan ODT was surveyed. Electronic pharmacy claims were reviewed to determine the number of patients who were successfully converted from sumatriptan to rizatriptan ODT. Pharmacy expenditures and total health care utilization and expenditures in the 180 days prior to (baseline) and after the conversion (followup) to rizatriptan ODT were compared for the cohorts of subjects who were successfully converted and those patients who were not successfully converted. RESULTS: Therapeutic conversion from sumatriptan to rizatriptan ODT was attempted in 457 patients; 214 (47%) were successfully converted. The only difference between the 2 cohorts at baseline for the 6 months prior to attempted conversion was a higher mean number of sumatriptan doses per patient per month (PPPM) in the 243 failed conversions (mean 3.5, SD 2.9) compared with the 214 successful conversions (mean 2.8, SD 2.8, P =0.003). The median triptan doses increased by 1.0 PPPM in both cohorts (P =0.882), from 2.0 to 3.0 doses PPPM in the group of successful conversions and from 2.7 to 4.0 in the group of unsuccessful conversions. The survey response rate was 55% for both successful and for unsuccessful conversions. More than 90% of the patients in both cohorts were satisfied with the level of care provided by the clinical pharmacy staff during medication conversion, and there was no difference between the 2 cohorts in patient satisfaction (P=0.761). Rizatriptan ODT was preferred by 68.0% and 8.5% of successful and failed conversion subjects, respectively (P less than0.001). Using representative group purchase prices, triptan expenditures for successful conversion subjects were reduced by a median of -$2 (6 %) PPPM while triptan expenditures for unsuccessful conversions increased by a median of $8 (P less than0.001). There were no differences for either cohort in median PPPM changes in migraine-related office visits (0.0 median change in office visits, P =0.748) or office-visit costs ($0 median change, P =0.861) for preconversion versus postconversion attempts Regression modeling identified that lower total counts of sumatriptan doses filled during baseline period was an independent predictor of successful conversion to rizatriptan ODT (P less than0.001). There was an average of 3.5 triptan medication fills per patient for successful conversion during the 6-month follow-up period, with 78% of these subjects filling at least 2 prescriptions for rizatriptan ODT during this period. CONCLUSIONS: This conversion program for sumatriptan to rizatriptan ODT was successful in converting almost half of primary care patients to the preferred product despite the absence of a copayment incentive for members to agree to the conversion. There were no measurable medical or economic consequences of the conversion, and patient satisfaction with the quality of care was maintained. Future efforts are likely to have a higher success rate if focused on converting patients with less-severe migraine headaches, as measured by the need for baseline rescue medication, since lower acuity was the only independent predictor of successful conversion in this conversion program for 2 triptan drugs.
- Open Access
- 1 October 2005
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care Pharmacy
- Vol. 11 (8) , 681-686
Clinical and Economic Outcomes of Conversion of Simvastatin to Lovastatin in a Group-Model Health Maintenance Organization
OBJECTIVE: To (a) determine if converting patients on simvastatin to lovastatin affects whether they meet their low-density lipoprotein cholesterol (LDL-C) goals as defined by the National Cholesterol Education Program Adult Treatment Panel III (ATP III) clinical practice guidelines and (b) assess the change in health care expenditures associated with such a conversion. METHODS: Primary and secondary prevention patients receiving simvastatin 10 mg to 40 mg daily between September 1, 2001, and February 28, 2002, were offered lovastatin at a therapeutically equivalent dose. Fasting lipid profiles and alanine aminotransferase (ALT) levels were measured and recorded at least 6 weeks after starting lovastatin. A clinical pharmacy staff member, in collaboration with the subjects primary care provider, subsequently adjusted lipid-lowering therapy as needed to attain target LDL-C goals, as determined by the ATP III clinical practice guidelines. RESULTS: Of 5,286 patients converted to lovastatin and for whom follow-up laboratory tests were drawn, 5,046 (95.5%) were converted successfully, and 240 (4.5%) had to be converted back to simvastatin due to intolerance (N=164, 3.1%) or failure to achieve LDL-C goal (N=76, 1.4%). The proportion of patients with LDL-C at or less than their target goal increased from 75.9% before the intervention to 79.1% after conversion to lovastatin (P less than 0.001). ALT levels did not change significantly. The mean ALT value, a proxy measure of safety before and after conversion for all patients, was 26.9 IU/L and 26.4 IU/L, respectively (P=0.134). For the 2,235 patients converted from lovastatin 80 mg to simvastatin 40 mg, the mean pre-ALT and post-ALT values were 26.9 IU/L and 26.5 IU/L (P=0.498). The annualized cost savings due to the conversions, expressed across the entire membership of this health maintenance organization (HMO), was $4.14 per member per year (PMPY), with no change in ALT levels. Patient savings in reduced copayments in the conversion from brand simvastatin to generic lovastatin were an average of $145.29 (62%) per patient (95% confidence interval, $143-$149, P less than 0.001). CONCLUSION: A clinical pharmacy-directed program designed to convert patients from simvastatin to lovastatin resulted in substantial expenditure reductions for this HMO and 62% copayment savings for members, without compromise in clinical outcomes as measured by lipid control (effectiveness) and ALT levels (safety). The proportion of patients at or less than their LDL-C goal increased coincident with the conversion from simvastatin to lovastatin.
- 1 October 2005
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care Pharmacy
- Vol. 11 (8) , 681-686
Open AccessClinical and Economic Outcomes of Conversion of Simvastatin to Lovastatin in a Group-Model Health Maintenance Organization
OBJECTIVE: To (a) determine if converting patients on simvastatin to lovastatin affects whether they meet their low-density lipoprotein cholesterol (LDL-C) goals as defined by the National Cholesterol Education Program Adult Treatment Panel III (ATP III) clinical practice guidelines and (b) assess the change in health care expenditures associated with such a conversion. METHODS: Primary and secondary prevention patients receiving simvastatin 10 mg to 40 mg daily between September 1, 2001, and February 28, 2002, were offered lovastatin at a therapeutically equivalent dose. Fasting lipid profiles and alanine aminotransferase (ALT) levels were measured and recorded at least 6 weeks after starting lovastatin. A clinical pharmacy staff member, in collaboration with the subjects primary care provider, subsequently adjusted lipid-lowering therapy as needed to attain target LDL-C goals, as determined by the ATP III clinical practice guidelines. RESULTS: Of 5,286 patients converted to lovastatin and for whom follow-up laboratory tests were drawn, 5,046 (95.5%) were converted successfully, and 240 (4.5%) had to be converted back to simvastatin due to intolerance (N=164, 3.1%) or failure to achieve LDL-C goal (N=76, 1.4%). The proportion of patients with LDL-C at or less than their target goal increased from 75.9% before the intervention to 79.1% after conversion to lovastatin (P less than 0.001). ALT levels did not change significantly. The mean ALT value, a proxy measure of safety before and after conversion for all patients, was 26.9 IU/L and 26.4 IU/L, respectively (P=0.134). For the 2,235 patients converted from lovastatin 80 mg to simvastatin 40 mg, the mean pre-ALT and post-ALT values were 26.9 IU/L and 26.5 IU/L (P=0.498). The annualized cost savings due to the conversions, expressed across the entire membership of this health maintenance organization (HMO), was $4.14 per member per year (PMPY), with no change in ALT levels. Patient savings in reduced copayments in the conversion from brand simvastatin to generic lovastatin were an average of $145.29 (62%) per patient (95% confidence interval, $143-$149, P less than 0.001). CONCLUSION: A clinical pharmacy-directed program designed to convert patients from simvastatin to lovastatin resulted in substantial expenditure reductions for this HMO and 62% copayment savings for members, without compromise in clinical outcomes as measured by lipid control (effectiveness) and ALT levels (safety). The proportion of patients at or less than their LDL-C goal increased coincident with the conversion from simvastatin to lovastatin.